Red yeast rice ‘safely’ reduces cholesterol levels and inflammatory markers: Italian study


- Last updated on GMT

Related tags: Red yeast rice, C-reactive protein, Inflammation

Red yeast rice ‘safely’ reduces cholesterol levels and inflammatory markers: Italian study
A daily dose of red yeast rice safely reduces elevated cholesterol levels, decreases a marker of inflammation, and lowers markers of vascular remodeling, says a new study from Italy that further supports the safety and efficacy of the supplement.

Red yeast rice is the product of yeast grown on rice. It is a dietary staple in some Asian countries, and reportedly contains several compounds that inhibit cholesterol production, including monacolin K – also known as lovastatin and used in Merck’s Mevacor pharmaceutical.

The scientific support for red yeast rice (RYR) includes a positive opinion from EFSA’s Panel on Dietetic Products, Nutrition and Allergies (NDA) that red yeast rice can maintain normal blood LDL-cholesterol concentrations​.

Despite this positive opinion, researchers from the Universities of Bologna and Pavia in Italy claim that the ingredient has not been tested in all populations, including the Italian population. 

Writing in Nutrition Research​, the researchers report that four weeks of supplementation with red yeast rice (10 mg monacolins from Monascus purpureus​ and 10 mg coenzyme Q10, supplied by Labomar s.r.l., Italy) resulted in average reductions in total cholesterol of 12.5%, and LDL cholesterol of 22%.

In addition, high-sensitivity C-reactive protein (hs-CRP), an established marker of inflammation, was reduced by an average of 24% in the mildly hypercholesterolemic, but otherwise healthy, Italian subjects.

“On the basis of our data, a nutraceutical containing 10 mg of monacolins appears to safely reduce cholesterolemia, hs-CRP, and markers of vascular remodeling in Mediterranean subjects,”​ wrote the Italian

Study details

The researchers recruited 25 people with mildly elevated cholesterol levels to participate in their double-blind, placebo-controlled randomized clinical trial. The volunteers were assigned to consume a ‘stabilization diet’ for four weeks, and then randomly assigned to receive the red yeast rice/CoQ10 supplements or placebo for an additional four weeks.

Results showed that, compared to placebo, the active supplement group had significant reductions in total cholesterol, LDL cholesterol, and non-HDL cholesterol.

In addition, the researchers measured levels of matrix metalloproteinases (MMPs) 2 and 9, which have been reported to be increased in people after a heart attack, in people with unstable angina, and after coronary angioplasty, they said. In this study, both MMP2 and 9 were decreased by 28 and 27%, respectively, following four weeks of supplementation with red yeast rice.

“This is probably related to the inflammation reduction, since it was observed that a decrease in hs-CRP and tumor necrosis factor alpha up-regulates the MMP expression through the activation of transcriptional factors,”​ they explained.

“However, the study duration was too short to observe any anatomical change in vessel structures, while the considered laboratory parameters are validated biomarkers of vascular stress,”​ they added.

Despite the positive results from this trial, albeit with a small sample size, and the positive opinion from the EFSA health claims panel, the Italian researchers called additional studies using larger patient samples and a longer duration.

Source: Nutrition Research
Published online ahead of print, doi: 10.1016/j.nutres.2013.05.015
“Red yeast rice improves lipid pattern, high-sensitivity C-reactive protein, and vascular remodeling parameters in moderately hypercholesterolemic Italian subjects”
Authors: A.F.G. Cicero, G. Derosa, A. Parini

Related topics: Research, Cardiovascular health

Related news

Related products

show more

MARKET FIRST: New MenaQ7® Full Spectrum Vit K2

MARKET FIRST: New MenaQ7® Full Spectrum Vit K2

NattoPharma USA, Inc. | 19-Mar-2018 | Product Brochure

Fermented cheeses are the best dietary source of menaquinones in the West, but most cannot consume enough daily to get optimal amounts of K2, nor is cheese...

NEW First Full-Spectrum Vitamin K2 from MenaQ7®

NEW First Full-Spectrum Vitamin K2 from MenaQ7®

NattoPharma USA, Inc. | 19-Feb-2018 | Data Sheet

Natural product consumers are drawn to comprehensive nutritional sources, but attaining our daily Vitamin K2 requirement from a Western diet is not a viable...

Setting Specifications – Don’t Forget To Do This!

Setting Specifications – Don’t Forget To Do This!

Gemini Pharmaceuticals | 12-Feb-2018 | Technical / White Paper

While the regulations require Brand Owners to establish specifications for all raw materials and for the finished product, based on the number of FDA Warning...


12 Reasons MenaQ7® is the Superior Vitamin K2

NattoPharma USA, Inc. | 11-Sep-2017 | Data Sheet

Vitamin K2 as MK-7 supplements are truly changing the face of global health, benefiting old and young alike. We know this because NattoPharma has single-handedly...

Related suppliers

Follow us


View more